{"product_id":"passagebio-five-forces-analysis","title":"Passage Bio Porter's Five Forces Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAnalyzes competition, buyer power, and entry barriers relevant to Passage Bio's success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003e Quickly spot opportunities and threats with a dynamic scoring system. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePassage Bio Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the complete Porter's Five Forces analysis of Passage Bio. The preview you see is the final document you'll receive. It's fully formatted and ready for immediate use. No alterations needed; it's ready to download. This document provides in-depth insights and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003ePorter's Five Forces Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003ePassage Bio faces a complex competitive landscape. Analyzing Porter's Five Forces reveals the intensity of rivalry, supplier power, and buyer influence. Understanding the threat of new entrants and substitutes is critical for strategic planning. This brief overview only hints at the detailed insights available. Unlock the full Porter's Five Forces Analysis to explore Passage Bio’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of suppliers in the genetic medicine sector is moderate. This is because specialized suppliers, like those providing viral vectors, hold some sway. For example, in 2024, the market for viral vectors was valued at around $1.5 billion. The concentration of these suppliers, and their importance to drug development, impacts Passage Bio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh switching costs can significantly boost supplier power. Passage Bio needs to evaluate the costs and time involved in changing suppliers for essential materials. For instance, if a specialized reagent has a sole source, the power of that supplier is amplified. In 2024, the pharmaceutical industry saw average switching costs of 10-15% of the contract value due to regulatory hurdles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Substitute Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIf substitutes for inputs are scarce, suppliers gain leverage. Passage Bio's reliance on unique or patented technologies could elevate supplier power. Assess the availability of alternative materials or technologies. For instance, in 2024, the gene therapy market saw increased competition, potentially impacting supplier dynamics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForward Integration Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers, especially those with forward integration potential, could significantly boost their bargaining power in the genetic medicines market. This means if a supplier, like a key raw materials provider, starts producing and selling gene therapies directly, they gain more control. Assessing the likelihood of this happening involves looking at the resources, expertise, and market strategies of major suppliers. For example, companies like Thermo Fisher Scientific, a major supplier of lab equipment and reagents, have expanded into gene therapy manufacturing services. This move increases their influence in the value chain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eThermo Fisher Scientific's revenue from biopharma services was $16.7 billion in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLonza Group, a key supplier of cell and gene therapy manufacturing, saw its sales grow by 11.4% in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe global gene therapy market is projected to reach $11.6 billion by 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Input on Cost\/Differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf Passage Bio heavily relies on specific, costly, or scarce raw materials or specialized services, suppliers gain leverage. The cost of goods sold (COGS) is a critical metric; any increase here directly impacts profitability. Consider the impact of proprietary technology or unique manufacturing processes. Strong supplier bargaining power can squeeze profit margins, especially if Passage Bio can't pass costs to consumers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCOGS percentage of revenue for biotechnology companies often ranges from 30% to 50%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe ability to switch suppliers is a key factor; limited options increase supplier power.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLong-term supply agreements can mitigate risks, but may lock in prices.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, the average cost of developing a new drug exceeded $2.6 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Dynamics in Genetic Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of suppliers in the genetic medicine field, like those providing essential materials, is moderate to high. High switching costs, such as regulatory hurdles, which average 10-15% of the contract value, enhance supplier power. The availability of substitutes significantly impacts supplier influence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eExample (2024 Data)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier Concentration\u003c\/td\u003e\n\u003ctd\u003eHigh concentration increases power.\u003c\/td\u003e\n\u003ctd\u003eViral vector market: ~$1.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching Costs\u003c\/td\u003e\n\u003ctd\u003eHigh costs increase power.\u003c\/td\u003e\n\u003ctd\u003eAvg. 10-15% of contract value.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput Scarcity\u003c\/td\u003e\n\u003ctd\u003eScarcity increases power.\u003c\/td\u003e\n\u003ctd\u003eGene therapy market: rising competition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForward Integration\u003c\/td\u003e\n\u003ctd\u003eIncreases supplier control.\u003c\/td\u003e\n\u003ctd\u003eThermo Fisher biopharma services: $16.7B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bargaining power of customers (healthcare providers, patients, and payers) for Passage Bio is moderate. This is because the gene therapies market is specialized. The concentration of buyers is relatively low, with a few major payers and hospital networks. These entities can negotiate prices, but the unique nature of gene therapies somewhat limits their power. In 2024, the average cost of gene therapy treatments ranged from $1 million to $3 million per patient, highlighting the high stakes in price negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow buyer switching costs can significantly amplify customer power, especially in the pharmaceutical sector. This happens because patients can readily opt for alternative treatments or therapies, increasing competition. Consider the availability of generic drugs, which offer similar efficacy at lower prices, making switching easier. In 2024, generic drugs accounted for approximately 90% of prescriptions filled in the U.S., underscoring the impact of low switching costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh price sensitivity can boost customer bargaining power, especially with cheaper alternatives. Evaluate Passage Bio's demand price elasticity for its therapies. In 2024, the average price of specialty drugs rose, indicating market sensitivity. This sensitivity impacts negotiation. Data from 2024 shows varying elasticity across different therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Information\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe bargaining power of customers is significantly influenced by the availability of information. Increased access to data on treatment options and pricing allows buyers to negotiate more effectively. Transparency in pricing and treatment information is crucial in the rare disease therapeutics market. This transparency impacts the ability of patients and payers to assess value and negotiate prices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePricing transparency remains limited in the rare disease market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatient advocacy groups are working to improve information access.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePayers are using cost-effectiveness analyses to negotiate prices.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe market value of rare disease drugs is projected to reach $330B by 2027.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFormulary Decisions and Payer Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFormulary decisions, made by insurance companies, heavily influence gene therapy adoption and pricing. Payers wield considerable power in negotiating prices and determining patient access. This can lead to significant challenges for Passage Bio's market entry and revenue generation. The influence of payers is crucial for understanding market access. For instance, in 2024, approximately 70% of US healthcare spending is managed care, highlighting payer importance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePayer negotiations impact pricing strategies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFormulary placement affects patient access.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket access is crucial for revenue generation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eManaged care's influence is significant in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Pricing \u0026amp; Payer Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power for Passage Bio is moderate due to the specialized gene therapy market, though payers and hospital networks can negotiate. High prices, with therapies costing $1-$3M in 2024, impact negotiations. Limited pricing transparency and payer influence, managing about 70% of U.S. healthcare spending in 2024, also play a role.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice of Gene Therapies\u003c\/td\u003e\n\u003ctd\u003eHigh costs impact negotiation.\u003c\/td\u003e\n\u003ctd\u003e$1M-$3M per patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer Influence\u003c\/td\u003e\n\u003ctd\u003eControls access, pricing.\u003c\/td\u003e\n\u003ctd\u003e70% of US healthcare spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Value of Rare Disease Drugs\u003c\/td\u003e\n\u003ctd\u003eGrowing market.\u003c\/td\u003e\n\u003ctd\u003eProjected $330B by 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eivalry Among Competitors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNumber of Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe competitive rivalry in the genetic medicines market is intense. Several companies, including Ultragenyx and Sarepta, are developing gene therapies. Passage Bio itself has a pipeline targeting rare CNS disorders. The market's growth, with projections exceeding $5 billion by 2024, attracts significant competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Growth Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA high industry growth rate generally eases competitive pressures. The gene therapy market for rare diseases is experiencing substantial expansion. The global gene therapy market was valued at approximately $6.1 billion in 2023. It is projected to reach around $20.2 billion by 2028, growing at a CAGR of 27.1% from 2023 to 2028. This rapid growth may lessen rivalry as more companies can find success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLimited product differentiation boosts competitive rivalry. If Passage Bio's therapies aren't unique, price and marketing become key battlegrounds. Evaluate how Passage Bio's treatments stand out from rivals. Data from 2024 shows this is crucial for survival.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExit Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh exit barriers significantly affect competitive rivalry. In the gene therapy industry, these barriers are substantial, encouraging companies to persist even when struggling. These barriers include significant investments in R\u0026amp;D, manufacturing, and clinical trials. The gene therapy market was valued at $5.7 billion in 2023, with expectations to reach $10.4 billion by 2028, showing a growing commitment from companies. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eHigh capital investments in specialized manufacturing facilities.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRegulatory hurdles, including FDA approvals, are costly and time-consuming.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe need for highly skilled scientific and technical personnel.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe moral and financial costs of abandoning clinical trials.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Stakes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh strategic stakes intensify competitive rivalry. Competitors in the rare disease market are highly motivated to capture market share. The rare disease market's strategic importance is increasing. In 2024, the global rare disease market was valued at approximately $250 billion. This drives intense competition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eMarket Value: The global rare disease market in 2024 is valued at about $250 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCompetitive Intensity: High stakes lead to aggressive market share battles.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic Focus: Companies prioritize rare disease treatments for growth.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMotivation: Competitors are highly driven to succeed.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Chart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Medicines: A Battleground of Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry in the genetic medicines market is marked by fierce competition among companies. The high growth of the gene therapy market, projected to reach $20.2 billion by 2028, attracts numerous players. Limited product differentiation and substantial exit barriers, such as high R\u0026amp;D costs, increase the competition's intensity. The strategic importance of the rare disease market, valued at $250 billion in 2024, further fuels this rivalry.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Growth\u003c\/td\u003e\n\u003ctd\u003eAttracts Competition\u003c\/td\u003e\n\u003ctd\u003eGene therapy market \u0026gt; $5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Differentiation\u003c\/td\u003e\n\u003ctd\u003eIntensifies Rivalry\u003c\/td\u003e\n\u003ctd\u003eRequires unique treatments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExit Barriers\u003c\/td\u003e\n\u003ctd\u003eEncourages Persistence\u003c\/td\u003e\n\u003ctd\u003eHigh R\u0026amp;D, manufacturing costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Stakes\u003c\/td\u003e\n\u003ctd\u003eDrives Competition\u003c\/td\u003e\n\u003ctd\u003eRare disease market $250B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069665292672,"sku":"passagebio-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/passagebio-five-forces-analysis.png?v=1749396673","url":"https:\/\/swotanalysistemplates.com\/products\/passagebio-five-forces-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}